Remove tag lung-cancer
article thumbnail

Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer

Fierce Pharma

Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.

300
300
article thumbnail

You can’t afford to get cancer

World of DTC Marketing

OPENING: American cancer patients spent more than $21 billion on their care in 2019. As cancer survival rates rise, so do the price tags of life-saving treatments. Some cancer patients may face out-of-pocket costs of nearly $12,000 a year for one drug. What makes cancer such a financial killer? ScienceNews.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

pharmaphorum

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.

article thumbnail

Uncovering the Hidden Gems within Your Datasets

PM360

One life science corporation leveraged real-world data to conduct a study based on a hypothesis that people were getting lung scans (e.g., chest X-rays) that may have shown incidental pulmonary nodules (IPNs) but were not followed up on for a variety of reasons,” Maloney offers as one example.

article thumbnail

Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs

PM360

This option grows more critical as new therapies become available with price tags as high as $3.5 Analysis of Time-to-Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small-Cell Lung Cancer.” million for the new hemophilia gene therapy. Blumenthal, G.M.

article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

Risk sharing agreements for lung cancer treatments make up 15% of all such agreements for oncology treatments, making it the largest indication for such approaches. In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”.

Marketing 102